Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esperanza Extract in Metastatic GI Tumors and Acute Leukemia
NCT05587088Phase 2Unknown
- Sponsor
- Hospital Universitario San Ignacio
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Herbal Medicine
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of petiveria alliacea extract in gastric cancer (GC), metastatic colorectal cancer (mCRC), biliary tract cancer (BTC) and 2 more (4 arms), sponsored by Hospital Universitario San Ignacio. Primary endpoints: Safety evaluation at 12 months and Efficacy evaluation at 12 months. Status: unknown.
02
Drugs
petiveria alliacea extract
03
Conditions
gastric cancer (GC)metastatic colorectal cancer (mCRC)biliary tract cancer (BTC)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05587088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05587088.